N/A
Completed N=161
ST-segment Elevation as an AF Endophenotype
Source: ClinicalTrials.gov NCT01205529 ↗Enrolled (actual)
161
Serious AEs
0.9%
Results posted
May 2018
Primary outcomePrimary: ST Segment Elevation ≥ 1.5 mm in the Right Precordial Leads (V1-V3), Either at Baseline or Manifested After Sodium Channel Block With Intravenous Procainamide — 4 Participants — p=1.0
Summary
The purpose of this study is to look for a similarity in people's genes that may help understand which people could benefit from certain drugs for the treatment of atrial fibrillation (AF).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY ST Segment Elevation ≥ 1.5 mm in the Right Precordial Leads (V1-V3), Either at Baseline or Manifested After Sodium Channel Block With Intravenous Procainamide |
4 | 1.0 |
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- Undergoing AF ablation at Vanderbilt or MGH
Exclusion Criteria
- Patients taking membrane active anti-arrhythmic drugs with sodium channel blocking properties (amiodarone, dronedarone, flecainide, propafenone) at the time of the ablation
- Patients with a history of Brugada syndrome or type 1 Brugada ECG pattern on the baseline ECG
- Patients with a history of drug-induced torsades de pointes
- Patients with a known history of hypersensitivity to procainamide, procaine or related drugs
- Patients with a history of systemic lupus erythematosus and myasthenia gravis
- Patients with a history of second degree AV block (Mobitz type II) or third degree AV block
- Women of child-bearing potential unless post-menopausal, surgically sterile, or have a negative pregnancy test day on the day of procedure
- Patients with dual chamber pacemakers or implantable defibrillators requiring ventricular pacing (uninterpretable ECG)
- Patients unable to give informed consent
Data sourced from ClinicalTrials.gov (NCT01205529). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.